Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001875620-25-000022
Filing Date
2025-08-13
Accepted
2025-08-13 11:20:43
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10127
2 JOINT FILING STATEMENT jointfilingstatementscvp.htm EX-1 5263
  Complete submission text file 0001875620-25-000022.txt   17242
Mailing Address 11 HUGHES IRVINE CA 92618
Business Address 11 HUGHES IRVINE CA 92618 949-427-7785
Beta Bionics, Inc. (Subject) CIK: 0001674632 (see all company filings)

EIN.: 475386878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94834 | Film No.: 251209673
SIC: 3841 Surgical & Medical Instruments & Apparatus
(CF Office: 08 Industrial Applications and Services)

Mailing Address C/O SANDS CAPITAL ALTERNATIVES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL ALTERNATIVES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by) CIK: 0001875620 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9